Throughout Cancer Research’s long publishing history, one of the Journal’s hallmarks has been the quality of the authors’ work. In this section, we are pleased to feature some of the most prominent authors published in Cancer Research–important researchers respected in their fields–along with their influential, highly cited articles.
José Baselga, MD, PhD
AACR President, 2015–16
José Baselga has contributed significantly to the clinical development and implementation of anti-HER2 antibodies for the treatment of HER2-positive breast cancer. His current research focuses on identifying mechanisms of resistance to targeted therapies for solid malignancies.
Stephen B. Baylin, MD
Stephen B. Baylin discovered that a number of tumor suppressor genes were hypermethylated, and hence silenced, during cancer. He continues to investigate epigenetic changes in cancer and the clinical efficacy of epigenetic-based therapies.
Isaac Berenblum, MD
The work of Isaac Berenblum laid the foundation required to understand the basic mechanism of carcinogenesis. His experiments demonstrated that chemical-induced carcinogenesis proceeds through three distinct stages known as initiation, promotion, and latency.
June L. Biedler, PhD
June L. Biedler investigated the genetic mechanisms by which patients acquire resistance to anticancer agents. Her work set in motion the eventual use of combination treatment strategies in a variety of malignancies.
John J. Bittner, PhD
AACR President, 1947–48
John J. Bittner was interested in the origins of cancer and investigated the inheritance of susceptibility factors. He discovered a transmissible “milk factor,” now known to be MMTV, a retrovirus, that promotes spontaneous mammary tumorigenesis in mice.
Roswell K. Boutwell, PhD
Roswell K. Boutwell investigated the mechanisms underlying the preventive effects of a low-calorie diet on cancer incidence. He helped to develop many of the experimental tools needed to effectively study nutrition and carcinogenesis.
Elisabeth Buchdunger, PhD
Elisabeth Buchdunger investigates the use of protein kinase inhibitors for cancer therapy. She has led research efforts towards the clinical development and implementation of imatinib for the treatment of CML, GIST, and other diseases.
Nancy L.R. Bucher, MD
The research interests of Nancy L.R. Bucher primarily centered around the regulatory mechanisms underlying liver regeneration. Her work using hepatocyte cultures has uncovered many important parallels between normal liver development and hepatic carcinogenesis.
Harris Busch, MD, PhD
AACR President, 1989–90
Harris Busch characterized the structures and contents of cancer cell nuclei and nucleoli. The morphological and molecular changes he identified within these organelles remain important for cancer diagnostics and have opened new avenues towards therapeutic development.
Abraham Cantarow, MD
AACR President, 1969–70
The research of Abraham Cantarow focused on calcium metabolism and the role of hormones in carcinogenesis. His studies on liver metabolism also provided insight into the uptake and clearance of systemically administered anticancer agents.
Paul P. Carbone, MD
AACR President, 1979–80
Paul P. Carbone conducted clinical oncology research focusing on cancer prevention. He also contributed to the development of a chemotherapeutic regimen that achieves high remission rates in patients with Hodgkin disease.
Susan P.C. Cole, PhD
Susan P.C. Cole investigates mechanisms of drug sensitivity and resistance mediated by membrane transport proteins. She discovered MRP1 (ABCC1), a membrane protein that promotes the efflux of anticancer agents and confers multidrug resistance to tumor cells.
Allan H. Conney, PhD
Allan H. Conney was interested in identifying enzymes and processes related to drug metabolism, providing the basis for the differential drug responses frequently observed in patients. He also investigated mechanisms of chemical carcinogenesis and chemoprevention.
Carlo M. Croce, MD
The research of Carlo M. Croce focuses on elucidating the genetic and molecular alterations underlying cancer, especially hematologic malignancies. He is currently investigating the tumor suppressive and oncogenic roles of microRNAs in various cancers.
Maynie R. Curtis, PhD
Maynie R. Curtis studied the effects of chemical carcinogens in animal models. She improved methods for experimentation in rats and was the first to demonstrate that liver sarcomas could be induced by a parasite infection.
Nancy E. Davidson, MD
AACR President, 2016–17
The work of Nancy E. Davidson provided significant insight into the role of the estrogen receptor in breast carcinogenesis. She currently pursues clinical and translational breast cancer research focused on the development of new treatment modalities.
Vincent T. Devita Jr
Vincent T. DeVita Jr helped to develop the four-drug combination therapy that essentially cured Hodgkin disease. He currently investigates the mechanisms underlying drug resistance and works to identify new molecular targets for combinatorial treatment strategies.
Gabriela Dontu, MD, PhD
The work of Gabriela Dontu confirmed the existence of cancer stem cells in solid tumors. Her research continues to focus on the identification and characterization of mammary stem cells during cancer initiation and progression.
Brian J. Druker, MD
Brian J. Druker developed Gleevec, a highly effective targeted therapy for AML that has radically improved patient survival rates. He continues to participate in translational research efforts aimed at generating and optimizing cancer treatments.
Wilhelmina F. Dunning, PhD
Wilhelmina F. Dunning investigated the carcinogenic mechanisms underlying tapeworm-induced liver sarcoma in rats. Her research areas of interest also extended to the effects of diet and hormones on cancer induction.
Emmanuel P. Farber, MD, PhD
AACR President, 1972–73
Emmanuel P. Farber was an experimental pathologist with an interest in understanding chemical carcinogenesis from a biological perspective. His work revealed that carcinogens can bind DNA and that cancer development proceeds in a stepwise fashion.
Isaiah J. Fidler, DVM, PhD
AACR President, 1984–85
The research of Isaiah J. Fidler aims to uncover the biology and therapy of cancer metastasis, particularly in the brain. His pivotal studies demonstrated that tumor cell populations are heterogeneous with varying metastatic potentials.
Judah Folkman, MD
Judah Folkman pioneered the idea that tumor growth requires the development of new blood vessels. His studies majorly impacted the tumor angiogenesis field, ultimately leading to the use of angiogenesis inhibitors for cancer therapy.
Joseph F. Fraumeni Jr
Joseph F. Fraumeni Jr helped to discover a hereditary cancer predisposition condition known as Li-Fraumeni syndrome. His research interests in cancer epidemiology have contributed to the identification of several environmental and genetic determinants of cancer.
Emil Frei, III, MD
Emil Frei focused his research efforts on developing treatments and cures for acute leukemias. His seminal findings that combination chemotherapy could achieve remission in pediatric leukemia were instrumental to modernizing cancer treatment.
Jacob Furth, MD
AACR President, 1957–58
Jacob Furth investigated the factors underlying the etiology and pathogenesis of leukemia. His work greatly contributed to an understanding of how viral, hormonal, and radiation agents affect carcinogenesis.
William U. Gardner, PhD
AACR President, 1946–47
William U. Gardner employed mouse models to examine the relationship between hormones and cancer. His work on various gynecologic and reproductive cancers shed light on the role of hormonal imbalance in tumorigenesis.
Theodore S. Hauschka, PhD
AACR President, 1959–60
Theodore S. Hauschka took a cytogenetic approach to investigate the genetic basis of cancer and other developmental disorders. His work integrating chromosomal studies and immunogenetics also helped to advance the field of tumor immunology.
Charles Heidelberger, PhD
The research of Charles Heidelberger focused on the metabolism of chemical carcinogens, cancer chemotherapeutic agents, and oncogenic transformation of cultured cells. He is credited with the development of the anticancer drug fluorouracil, which is still used today.
Rakesh K. Jain, PhD
Rakesh K. Jain investigates the influence of the tumor microenvironment on cancer pathogenesis. He helped to shape the concept of vessel normalization as a strategy for enhancing intratumoral delivery of anticancer drugs using angiogenesis inhibitors.
Peter A. Jones, PhD, Dsc.
AACR President, 2005–06
Peter A. Jones discovered a link between DNA methylation and cancer that revealed how tumor suppressors become silenced in malignant cells. He currently investigates the epigenetic changes underlying cancer phenotypes and the feasibility of epigenetic therapies.
Henry S. Kaplan, MD
AACR President, 1966–67
Henry S. Kaplan helped to develop the first medical linear accelerator for cancer radiotherapy, discovered that radiation-induced leukemia in mice was caused by a virus, and significantly contributed to the first cure for Hodgkin disease.
Kenneth W. Kinzler, PhD
Kenneth W. Kinzler discovered that mutations in the tumor suppressor gene APC, and within its signaling cascade, drive colorectal tumorigenesis. He currently focuses on developing novel genomic methods to identify genetic alterations and detect cancer early.
Eva Klein, MD, PhD
The work of Eva Klein continues to illuminate how interactions between B lymphocytes and the Epstein-Barr virus promote hematologic malignancies. Additionally, her work on natural killer cells influenced themes within the tumor immunology field.
George Klein, MD, PhD
George Klein discovered that Epstein-Barr virus infection underlies the development of lymphomas and other cancers. He currently investigates the factors and mechanisms associated with tumor resistance and the propensity for cancer incidence.
Lance A. Liotta, MD, PhD
Lance A. Liotta pioneered studies examining the role of the extracellular matrix in cancer metastasis. He developed technologies in the fields of molecular diagnostics, cancer molecular therapeutics, and microdissection, and continues research related to cancer proteomics.
Clarence C. Little, DSc.
AACR President, 1930–31; 1939–40
Clarence C. Little had a long-standing interest in mammalian genetics and hereditary factors contributing to cancer. He is responsible for establishing the first inbred strains of mice (i.e., C57BL/6) and initiating the first mouse research facility.
Lawrence A. Loeb, MD, PhD
AACR President, 1988-89
Lawrence A. Loeb explores the role of mutations in cancer incidence and progression. He proposed that cancer cells exhibit a mutator phenotype, a hypothesis that gained significant credence after recent tumor-sequencing efforts.
John Mendelsohn, MD
John Mendelsohn helped to develop the EGFR-targeted monoclonal antibody, cetuximab, for the treatment of colorectal and head and neck cancers. He participates in collaborations aimed at identifying patient-specific mutations that can be incorporated into personalized therapies.
Elizabeth C. Miller, PhD
AACR President, 1976–77
Elizabeth C. Miller helped to discover that foreign chemicals were not inherently carcinogenic, but became metabolically activated in the body. Her work on the metabolism of carcinogens spearheaded new eras of toxicology and pharmacology research.
James A. Miller, PhD
James A. Miller elucidated the metabolic mechanisms by which chemicals become carcinogenically active. He also pioneered research in enzymology that paved the way for subsequent seminal drug metabolism and interaction studies in the toxicology field.
Harold L. Moses, MD
AACR President, 1991–92
The work of Harold L. Moses led to the discovery of TGF-β and its tumor-suppressive role in cancer, providing new insight into the signaling networks regulating physiologic and pathologic cell growth.
Gerald C. Mueller, MD, PhD
AACR President, 1982–83
The work of Gerald C. Mueller was fundamental towards understanding the mechanism of action of estrogens and related receptors. He also developed valuable methods to investigate the growth and differentiation of normal and neoplastic cells.
Peter C. Nowell, MD
Peter C. Nowell helped to discover that patients with chronic myeloid leukemia harbored a chromosomal translocation, now known as the Philadelphia chromosome. His subsequent work identifying chromosomal aberrations in other lymphoid malignancies further advanced tumor cytogenetics.
Lloyd J. Old, MD
Lloyd J. Old was one of the early pioneers of tumor immunology. Though poorly received in the past, his research on early cancer immunotherapies formed the basis necessary to boost the status of this remarkable field.
Van R. Potter, PhD
AACR President, 1974–75
Van R. Potter took a biochemical approach to cancer research, making significant contributions to an understanding of cancer metabolism, oncogenic transformation, and driver versus passenger mutations in carcinogenesis. He also established the field of bioethics.
Steven A. Rosenberg, MD, PhD
The research of Steven A. Rosenberg dramatically propelled the cancer immunotherapy field. He developed adoptive T-cell transfer, which led to remarkable remission rates in metastatic melanoma. He continues investigating patient immune responses to cancer.
Harold P. Rusch, MD
AACR President, 1953–54
Harold P. Rusch investigated the carcinogenic effects of ultraviolet radiation and chemical compounds. He was also interested in mechanisms underlying cell growth and differentiation, using the slime mold as a model system.
Regina Schoental, PhD, DSc
Regina Schoental investigated the carcinogenic properties of naturally occurring toxins, such as polycyclic aromatic hydrocarbons. Her studies on the metabolites of toxic substances found in plants, food, fungus, and coal tar greatly advanced the environmental toxicology field.
David Sidransky, MD
David Sidransky has a long-standing interest in developing molecular approaches for the early detection of cancer. His work aims to identify the genetic changes underlying the progression of head and neck, lung, and bladder cancers.
Howard E. Skipper, PhD
Howard E. Skipper investigated the responses of malignant cells to anticancer agents. He developed detailed protocols for appropriate drug dosing that maximized cancer cell killing, transforming the way combination chemotherapy was administered to patients.
Michael B. Sporn, MD
The research interests of Michael B. Sporn primarily focus on cancer prevention efforts through chemoprevention. His lab continues to synthesize and test pharmacologic agents intended to impede the development of breast, pancreatic, and lung cancer.
Takashi Sugimura, MD, PhD
Takashi Sugimura investigated the carcinogenic properties and structures of mutagens, including those arising in cooked foods. His work establishing cancer as a disease of DNA further led to the co-identification of the DNA repair enzyme, PARP.
Albert Tannenbaum, MD
AACR President, 1956–57
Albert Tannenbaum investigated the link between nutrition and cancer incidence. His observations that caloric restriction was related to reduced tumor formation were seminal to understanding how diet could accelerate, and even prevent, carcinogenesis.
Craig B. Thompson, MD
The work of Craig B. Thompson spanned many facets of cancer research, including immune system homeostasis, mechanisms of apoptosis, and metabolism. He continues to investigate nutrient-sensing pathways and the bioenergetic requirements of tumor cells.
Helene W. Toolan, PhD
Helene W. Toolan investigated mechanisms of carcinogenesis by using tumor transplantation models. Her studies on the relationship between viral infection and human cancer incidence helped to shape the cancer virology field.
Axel Ullrich, PhD
The research of Axel Ullrich heavily focuses on medical applications of biotechnology. He helped to develop trastuzumab for the treatment of breast cancer and provided proof of concept that targeting receptor tyrosine kinases was therapeutically beneficial.
Bert Vogelstein, MD
The research of Bert Vogelstein centers around cancer genetics. His fundamental model that the sequential accumulation of mutations in oncogenes and tumor suppressors causes cancer led to the discovery of several critical cancer driver genes.
Lee W. Wattenberg, MD
AACR President, 1992–93
Lee W. Wattenberg made major breakthroughs in the chemoprevention field by showing that some compounds can block carcinogenesis in experimental animals. His studies on synthetic and dietary agents illuminated many new cancer prevention strategies.
Robert A. Weinberg, PhD
Robert A. Weinberg is credited with the discovery of the first oncogene, RAS, and the first tumor suppressor gene, RB. His work continues to focus on the mechanisms underlying cancer progression and metastasis.
I. Bernard Weinstein, MD
AACR President, 1990–91
I. Bernard Weinstein greatly advanced the field of chemical carcinogenesis through his findings related to environmental carcinogens. He also introduced his theory of oncogene addiction, a notion that has significantly impacted the design of cancer therapeutics.
Max S. Wicha, MD
Max S. Wicha has made seminal contributions to the cancer stem cell field, including the first identification of breast cancer stem cells. His current research efforts focus on developing therapeutic interventions that target this tumor population.
Timeline | Influential Articles | Nobel Laureates | Highly Cited Authors | Milestones